Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.
about
The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertensionVardenafil for the treatment of erectile dysfunction: an overview of the clinical evidenceSympathetic skin response in patients with vascular erectile dysfunction.The SIAMS-ED Trial: A National, Independent, Multicentre Study on Cardiometabolic and Hormonal Impairment of Men with Erectile Dysfunction Treated with Vardenafil.Oral drug treatments in patients with erectile dysfunction and multiple comorbidities: a retrospective observational study.Survivorship: sexual dysfunction (male), version 1.2013Survivorship: sexual dysfunction (female), version 1.2013.Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbiditiesDoes vitamin D deficiency contribute to erectile dysfunction?Correlates of PDE5i use among subjects with erectile dysfunction in two population-based surveys.Attitudes and Performance of Cardiologists Toward Sexual Issues in Cardiovascular Patients.Computational methods using genome-wide association studies to predict radiotherapy complications and to identify correlative molecular processes.Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors.PDE5 inhibitors: considerations for preference and long-term adherence.Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors.Hemodynamic effect of avanafil and glyceryl trinitrate coadministration.Taking the stress out of treating erectile dysfunction.Erectile dysfunction may improve by blood pressure control in patients with high-risk hypertension.Obstructive sleep apnea associated with erectile dysfunction and cardiovascular disease.Erectile dysfunction and the "window of curability": a harbinger of cardiovascular events.Association of metabolic syndrome, atherosclerosis risk factors, sex hormones in ED in aboriginal Taiwanese.Sildenafil for erectile dysfunction in the Middle East: observational analysis of patients with diabetes and/or hypertension treated in the clinical practice setting.Phosphodiesterase type 5 and cancers: progress and challenges.Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Time-course changes of nLDL-induced erectile dysfunction.
P2860
Q26852171-F358B0D3-00E2-4C7E-9488-7A3F70503513Q33571010-04D5B667-1983-43DC-BB16-8A2EA8681231Q33632146-6866CED2-0380-45AA-845F-B379806CE4F4Q33737324-79B14321-93D2-435F-A7BA-B8077CE4676DQ33880138-E8830A54-863B-4FAD-B1BF-2C94CBEC4DCBQ35735012-EC9A6F59-0DF5-49EA-A6DB-976AEBF255EDQ35735025-4DA6C356-A3F4-4421-AE96-37E96716902FQ35840149-9A93FD70-4C0E-4DA8-9468-0E310C72B9DEQ36187592-EDF188B7-B280-4C02-B8C9-14F71F418B4CQ36542984-DB935F63-ACBC-4399-A128-CF1A0AAAE18CQ37636063-D8B2E9CF-0230-485C-A7FA-3C18011B17F9Q37663082-A5E3170A-5799-409A-9C93-C1EB33941BC2Q37903037-4853B060-D1D5-4A82-B0C3-1AF5FD69BC98Q38122721-CF0CAB60-8A74-45EE-9D9F-5039B7D55492Q38126803-843BE664-7CAD-459E-B3B4-9A03FC9268BBQ39105942-30586C1B-6092-4D72-BB6E-CEAC4E6D895BQ41859015-CCE6CB74-6166-4198-8C56-F91F8C732D06Q42103057-AFF254FD-A1AF-467B-ABF6-54FCE8108447Q42805340-A96C618E-1824-45D9-8F41-5BF1928CC093Q43120387-DE379136-9C58-4867-94AE-467A0C53012DQ43151301-91A76D4B-21D5-46E9-AA41-8C1AF6E2E44DQ45032186-CB4129EB-EB12-442B-BAB6-5333CAD77D01Q46794096-4E056683-EAA9-42B9-BBE4-2ABEB2C30428Q47171803-FE403994-3067-4297-B87A-DD020ABBE107Q47650581-D830A83F-EC1A-464F-8DFD-3702CC0FC02BQ50797097-DAC15F44-7A32-48DB-8651-139FE82743DA
P2860
Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Erectile dysfunction and cardi ...... s in men with both conditions.
@en
Erectile dysfunction and cardi ...... s in men with both conditions.
@nl
type
label
Erectile dysfunction and cardi ...... s in men with both conditions.
@en
Erectile dysfunction and cardi ...... s in men with both conditions.
@nl
prefLabel
Erectile dysfunction and cardi ...... s in men with both conditions.
@en
Erectile dysfunction and cardi ...... s in men with both conditions.
@nl
P2860
P356
P1476
Erectile dysfunction and cardi ...... s in men with both conditions.
@en
P2093
Ajay Nehra
P2860
P304
P356
10.4065/84.2.139
P407
P577
2009-02-01T00:00:00Z